Status: Recruiting
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors. The main goals of this study are to: * Find the recommended dose of TS-104 that can safely be given to participants * Learn more about the side effects of TS-104 * Learn more about the effectiveness of TS-104 * Learn more about the pharmacokinetics of TS-104
Participants needed: 74
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: TwoStep Therapeutics, Inc.Updated: Sep 30, 2026Locations: 3
Eligibility criteria
Males & females ≥18 years of age at the time of consent [+19]
Unresolved toxicity higher than Grade 1 Common Terminology Criteria for Adverse... [+16]